成都{静脉炎}在线医生免费问成都哪个医院治疗静脉曲张的好,成都检查静脉曲张多少钱,成都淋巴水肿医院排名,成都血管畸形哪儿治疗比较好,成都治疗腿部{静脉炎}哪里好,成都中医如何治疗好静脉血栓,成都鲜红斑痣手术

White House chief of staff John Kelly has been locked in an internal struggle with President Donald Trump's son-in-law and senior adviser Jared Kushner over his access to highly classified information for weeks now, a confrontation that has escalated amid a recent policy overhaul and the resignation of a staff secretary who was accused of spousal abuse.The dispute has deepened a growing rift between Kelly and Kushner, who initially welcomed the new system of rigor instituted by the chief of staff but has since grown frustrated by what he views as attempts to limit his access to the President.Kelly distributed a five-page memo Friday announcing that the White House will no longer allow some employees with interim security clearances to access to top secret information if their background investigation has been pending since before last June -- a category Kushner falls into.  899

With 20 electoral votes at stake, all eyes will be on Pennsylvania on Election Day. However, officials warn that counting the ballots could take days.In Bucks County, a heavily populated suburban county near Philadelphia has a population of about 628,000 people. In 2016, Hillary Clinton won the county by a narrow lead with a few thousand votes. This time around, both presidential campaigns have been courting the suburban vote, and the suburban Philadelphia counties are considered critical. Polls across the state closed at 8 p.m. EST, and now the more than 2 million mail-in ballots the state has received can now be counted. “We sent out about 200,000 ballots, which is 10 times more than we did four years ago, and we've gotten back somewhere in the area 160,000,” said Bob Harvie, Bucks County, Pennsylvania Board of Elections Chairman. “We still have mail coming in obviously today that we can accept. We had U.P.S. dropping off some ballots. We've got drop boxes that will be emptied at 8, and those will be brought here, and we don't know how much will be in those.” In Pennsylvania, more than 2 million mail-in ballots have been returned so far. The state doesn’t have a lot of experience dealing with large amounts of mail-in ballots, unlike places like Colorado, Washing, and even Florida and Arizona, where ballots have been counted as they come in. However, in Bucks County, officials didn’t begin counting ballots until after the polls closed, and a handful of Pennsylvania counties won’t start counting until tomorrow. “It's been a big challenge. It has been, you know, primarily because we were not even able toopen the envelopes until today. And there's a security envelope. So, that's two envelopes you need to open. You need to be able to make sure that everything is on there, their name, their address, the date,” said Diane Marseglia, Bucks County Board of Elections. “So, you're checking for a lot of things all at the same time and then you're pulling it out, and then, you're going to start to gather them for a vote. That's a lot of time.”If the presidential race hinges on Pennsylvania, it’s possible we won’t know who won the presidency for days.E.W. Scripps national correspondent Maya Rodriguez is in the Keystone State, bringing you the latest on Election Day. 2302

When Jeff Hill returned to his neighborhood in Paradise, California, after evacuating during the Camp fire, he came across a wayward horse -- in a backyard swimming pool. The horse appeared to have jumped in to escape the flames, and was caught in the pool cover.He had been checking on a neighbor's house to see if it was still standing when he discovered the horse, Hill wrote in a Facebook post."We scrambled to unhook the pool cover and pulled her to the shallow end where we guided her up the steps." The horse got out, shook off, and "loved on us for a few minutes as a thank you, and walked off," he wrote.Hill called for help, and waited with the horse until resources could escort the horse out from the fire zone.As wildfires raged in different parts of California, residents were forced to evacuate -- some without getting the chance to go home and grab their four-legged friends.Searchers combing through the charred areas have rescued hundreds of animals -- including dogs, cats, horses, donkeys, ducks, and a tortoise.Now, community organizations and good Samaritans are rallying to shelter the displaced animals and reunite them with their owners. 1170

White House officials have told congressional leaders and appropriators that President Donald Trump does not want any additional relief funding sent to Puerto Rico, a congressional leadership aide told CNN on Monday.While there are no talks to cut funds that have already been appropriated, a White House aide said negotiations have focused on keeping Puerto Rico relief funding out of a supplemental spending bill that would fund relief efforts in parts of the south that were ravaged by hurricanes this year.That aide noted Puerto Rican officials haven't yet spent all the money Congress has set aside for them, and said the administration is moving to stop any more money from going to help the island "because they don't need it and will most likely not be able to spend it."Trump's latest positioning on Puerto Rico was first reported by Axios. The White House has been making this known on Capitol Hill for "a while now," the congressional leadership aide said.Trump has previously taken aim at Puerto Rican officials?for their management of the billions in relief funds his administration has appropriated for storm recovery, accusing the island's leaders of spending some of that money for reasons other than hurricane clean-up."The people of Puerto Rico are wonderful but the inept politicians are trying to use the massive and ridiculously high amounts of hurricane/disaster funding to pay off other obligations," Trump tweeted on October 23. "The U.S. will NOT bail out long outstanding & unpaid obligations with hurricane relief money!"More than a month earlier, the President had repeatedly dismissed a widely cited death toll that placed the number of lives lost in Hurricanes Irma and Maria around 3,000 by claiming Democrats had exploited the numbers to make his administration look bad. There has been no evidence to indicate that partisan politics has played a role in the calculation of the death tally, and George Washington University, which conducted the study to calculate the death toll, released a statement at the time that said it stands by its work.Talks over stopping future funding for Puerto Rico come as lawmakers look to avoid a government shutdown when temporary spending bills expire in early December. The funding fight could be the last of Trump's presidency waged by a Republican-controlled Congress, as Democrats have an incoming majority in the House.The White House did not immediately respond to a request for comment. A spokesman for Puerto Rican Gov. Ricardo Rossello could also not be reached for comment.In October, the government of Puerto Rico rolled out a five-year economic blueprint that included billion in federal hurricane recovery relief. The plan was approved by a federal control board, which oversees the island's finances. The board's executive director Natalie Jaresko said at the time the funds would not be budgeted for debt payments, but rather to help stimulate the economy.In February, Puerto Rico received billion in federal aid under a disaster relief package signed by Trump.The funding for the devastated island was part of a billion package agreed upon by Senate leaders as part a two-year budget deal to avert a government shutdown. The relief deal covered a number of major disasters across the US, including Hurricanes Maria, Irma and Harvey, and wildfires in California.Puerto Rico had estimated it would need billion to rebuild the devastated island after two destructive hurricanes hit, shredding its power grid and infrastructure. 3555

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines work by tricking the body into thinking there’s an infection so it makes antibodies and remembers how to do that if the real bug turns up.But it can take a month or two after vaccination or infection for the most effective antibodies to form. The experimental drugs shortcut that process by giving concentrated versions of specific ones that worked best against the coronavirus in lab and animal tests.“A vaccine takes time to work, to force the development of antibodies. But when you give an antibody, you get immediate protection,” said University of North Carolina virologist Dr. Myron Cohen. “If we can generate them in large concentrations, in big vats in an antibody factory ... we can kind of bypass the immune system.”These drugs are believed to last for a month or more and could give quick, temporary immunity to people at high risk of infection, such as health workers and housemates of someone with COVID-19. If they proved effective and if a vaccine doesn’t materialize or protect as hoped, the drugs might eventually be considered for wider use, perhaps for teachers or other groups.They’re also being tested as treatments, to help the immune system and prevent severe symptoms or death.“The hope there is to target people who are in the first week of their illness and that we can treat them with the antibody and prevent them from getting sick,” said Dr. Marshall Lyon, an infectious disease specialist helping to test one such drug at Emory University in Atlanta.Having such a tool “would be a really momentous thing in our fight against COVID,” Cohen said.Vaccines are seen as a key to controlling the virus, which has been confirmed to have infected more than 20 million people worldwide and killed more than 738,000. Several companies are racing to develop vaccines, but the results of the large final tests needed to evaluate them are months away.The antibody drugs are “very promising” and, in contrast, could be available “fairly soon,” said Dr. Janet Woodcock, a U.S. Food and Drug Administration official who is leading government efforts to speed COVID-19 therapies. Key studies are underway and some answers should come by early fall.One company, Eli Lilly, has already started manufacturing its antibody drug, betting that studies now underway will give positive results.“Our goal is to get something out as soon as possible” and to have hundreds of thousands of doses ready by fall, said Lilly’s chief scientific officer, Dr. Daniel Skovronsky.Another company that developed an antibody drug cocktail against Ebola — Regeneron Pharmaceuticals Inc. — now is testing one for coronavirus.“The success with our Ebola program gives us some confidence that we can potentially do this again,” said Christos Kyratsous, a Regeneron microbiologist who helped lead that work.Regeneron’s drug uses two antibodies to enhance chances the drug will work even if the virus evolves to evade action by one.Lilly is testing two different, single-antibody drugs — one with the Canadian company AbCellera and another with a Chinese company, Junshi Biosciences. In July, Junshi said no safety concerns emerged in 40 healthy people who tried it and that larger studies were getting underway.Others working on antibody drugs include Amgen and Adaptive Biotechnologies. The Singapore biotech company Tychan Pte Ltd. also is testing an antibody drug and has similar products in development for Zika virus and yellow fever.“I’m cautiously optimistic” about the drugs, said the nation’s top infectious diseases expert, Dr. Anthony Fauci. “I’m heartened by the experience that we had with Ebola,” where the drugs proved effective.What could go wrong?— The antibodies may not reach all of the places in the body where they need to act, such as deep in the lungs. All the antibody drugs are given through an IV and must make their way through the bloodstream to wherever they’re needed.— The virus might mutate to avoid the antibody — the reason Regeneron is testing a two-antibody combo that binds to the virus in different places to help prevent its escape.Skovronsky said Lilly stuck with one antibody because manufacturing capacity would essentially be cut in half to make two, and “you will have less doses available.” If a single antibody works, “we can treat twice as many people,” he said.— The antibodies might not last long enough. If they fade within a month, it’s still OK for treatment since COVID-19 illness usually resolves in that time. But for prevention, it may not be practical to give infusions more often than every month or two.A San Francisco company, Vir Biotechnology Inc., says it has engineered antibodies to last longer than they usually do to avoid this problem. GlaxoSmithKline has invested 0 million in Vir to test them.Giving a higher dose also may help. If half of antibodies disappear after a month, “if you give twice as much, you will have two months’ protection,” Lilly’s Skovronsky said.— The big fear: Antibodies may do the opposite of what’s hoped and actually enhance the virus’s ability to get into cells or stimulate the immune system in a way that makes people sicker. It’s a theoretical concern that hasn’t been seen in testing so far, but large, definitive experiments are needed to prove safety.“As best as we can tell, the antibodies are helpful,” Lyon said.___Marilynn Marchione can be followed on Twitter: @MMarchioneAP___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5919